KEGG   DRUG: Darunavir and cobicistatHelp
Entry
D10832            Mixture   Drug                                   

Name
Darunavir and cobicistat;
Prezcobix (TN);
Rezolsta (TN)
Product
Component
(Darunavir ethanolate [DR:D06478] | Darunavir [DR:D03656]), Cobicistat [DR:D09881]
Remark
Therapeutic category: 6250
ATC code: J05AR14
Product: D10832<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Darunavir is a substrate of CYP3A; it is also an inhibitor of CYP3A, CYP2D6 and P-gp.
Cobicistat is a substrate of CYP3A and CYP2D6; it is also an inhibitor of CYP3A, CYP2D6, P-gp, BCRP, OATP1B1 and OATP1B3.
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR14 Darunavir and cobicistat
      D10832  Darunavir and cobicistat <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Agents, Other
   Darunavir/ Cobicistat
    D10832  Darunavir and cobicistat
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10832  Darunavir and cobicistat
Antiinfectives [br08350.html]
 Antivirals
  D10832
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10832
BRITE hierarchy
Other DBs
PubChem: 319902632
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system